$0.955
+0.010 (+1.06%)收盤時
- High
- 0.980
- Open
- 0.965
- VWAP
- 0.95
- Vol
- 14.23K
- Mkt Cap
- —
- Low
- 0.925
- Amount
- 13.57K
- EV/EBITDA, TTM
- 0.00
PomDoctor Ltd is a holding company principally engaged in the operation of online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment includes providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment includes pharmacy retail sales and wholesale. The Company mainly conducts its business in the domestic market.
AI analysis of PomDoctor Ltd (POM)
holdCurrently, PomDoctor Ltd is not a strong buy. The stock price is at 0.95, which is significantly down 83.80% year-to-date and 98.68% over the past year. The RSI is at 50.15, indicating a neutral momentum, and the forward P/E is at 0, suggesting a lack of earnings expectations. While there was a positive revenue growth of 16.7% reported for FY 2025, the gross margin has declined to 13.1%, indicating profitability pressures. The main risk is the company's negative equity of -2.26 billion CNY, which raises concerns about financial stability.
估值指標
事件時間軸
資訊
8.508-27PRnewswirePomdoctor Initiates U.S. Market Entry Preparations
- 7.507-15PRnewswire
Pomdoctor Enhances Healthcare Data Ecosystem
- 8.507-13PRnewswire
Pomdoctor Regains Nasdaq Compliance with Minimum Bid Price
8.507-13NewsfilterPomdoctor Regains Nasdaq Compliance with Minimum Bid Price
- 4.507-02PRnewswire
POMDOCTOR Transitions to Predictive Healthcare Infrastructure Provider
POM FAQ — answered by Alphio AI
PomDoctor Ltd is a holding company principally engaged in the operation of online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment includes providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment includes pharmacy retail sales and wholesale. The Company mainly conducts its business in the domestic market. It operates in the Healthcare sector.
Currently, PomDoctor Ltd is not a strong buy. The stock price is at 0.95, which is significantly down 83.80% year-to-date and 98.68% over the past year. The RSI is at 50.15, indicating a neutral momentum, and the forward P/E is at 0, suggesting a lack of earnings expectations. While there was a positive revenue growth of 16.7% reported for FY 2025, the gross margin has declined to 13.1%, indicating profitability pressures. The main risk is the company's negative equity of -2.26 billion CNY, which raises concerns about financial stability.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。